In conclusion, although pathway signatures derived from post-treatment samples are highly predictive of therapeutic response to anti-PD1 in patients with metastatic melanoma, further studies are warranted to confirm the predictive value of those signatures in larger cohorts of patients with metastatic melanoma. Here, PDCD1 is linked to metastatic melanoma.